DPI-125 is under clinical development by DMK Pharmaceuticals and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DPI-125’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights N

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DPI-125 overview

DPI-125 is under development for the treatment of pain and opioid use disorder (OUD). The drug candidate is administered as an intravenous formulation and as transdermal patch. It is a small molecule compounds with specific activity at the delta receptor. DPI-125 is a mixed delta/mu analgesic. Delta- and mu- opioid receptors are GPCRs of the nervous system. Opioid receptors are present in many regions of the nervous system that are involved in pain transmission and control, including primary afferent neurons, spinal cord, midbrain and thalamus. Opioids exert their pharmacological actions through delta and mu opioid receptors. Delta and mu opioid receptors in the brain are activated by a family of endogenous peptides like enkephalins, dynorphins and endorphin, which are released by neurons. Opioids produce effects on neurons by acting on receptors located on neuronal cell membranes. Opioids primarily act as inhibitory agents in the neural circuit. The drug candidate as a delta- and mu- opioid receptor agonist may inhibit the neurotransmitter release.

It was under development for acute post-operative pain and nociceptive pain.

DMK Pharmaceuticals overview

DMK Pharmaceuticals (DMK), formerly Adamis Pharmaceuticals Corporation, is a commercial-stage neuro-biotech company that develops and commercializes products for the treatment of opioid overdose and substance use disorders. The company’s pipeline includes SYMJEPI, ZIMHI, DPI-125, DPI-221 and DPI-289. Its pipeline candidates treat anaphylaxis, opioid overdose, opioid use disorder, benign prostatic hyperplasia and parkinson’s disease. DMK develops products in the form of injections, gels and capsules for the treatment of allergies, opioid overdose and respiratory and inflammatory disease. The company supplies its products to doctors, ambulatory surgery centers, healthcare systems, hospitals and veterinarians across the US. DMK is headquartered in San Diego, California, the US.

For a complete picture of DPI-125’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.